Syros Non Currrent Assets Other vs Other Stockholder Equity Analysis
SYRS Stock | USD 0.25 0.01 3.85% |
Syros Pharmaceuticals financial indicator trend analysis is much more than just breaking down Syros Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Syros Pharmaceuticals is a good investment. Please check the relationship between Syros Pharmaceuticals Non Currrent Assets Other and its Other Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.
Non Currrent Assets Other vs Other Stockholder Equity
Non Currrent Assets Other vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Syros Pharmaceuticals Non Currrent Assets Other account and Other Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Syros Pharmaceuticals' Non Currrent Assets Other and Other Stockholder Equity is 0.81. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Syros Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Syros Pharmaceuticals' Non Currrent Assets Other and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Syros Pharmaceuticals are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Non Currrent Assets Other i.e., Syros Pharmaceuticals' Non Currrent Assets Other and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Other Stockholder Equity
Most indicators from Syros Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.Issuance Of Capital Stock is likely to gain to about 86.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2024.
Syros Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Syros Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Syros Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 150.0M | 213.3M | 182.9M | 244.5M | 168.2M | 147.5M | |
Other Current Liab | 10.6M | 9.4M | 13.6M | 15.9M | 13.8M | 10.7M | |
Total Current Liabilities | 23.5M | 28.6M | 31.5M | 30.8M | 36.7M | 22.2M | |
Total Stockholder Equity | 79.2M | 90.6M | 85.2M | 127.7M | 16.7M | 15.8M | |
Other Liab | 22.6M | 29.6M | 3.0M | 24.5M | 28.1M | 29.5M | |
Net Tangible Assets | 79.2M | 125.4M | 106.1M | 148.6M | 170.9M | 179.4M | |
Property Plant And Equipment Net | 31.9M | 29.6M | 27.3M | 24.7M | 19.5M | 16.6M | |
Net Debt | (15.5M) | (107.8M) | (27.1M) | (103.9M) | (77.5M) | (81.3M) | |
Retained Earnings | (293.0M) | (377.0M) | (463.6M) | (558.2M) | (722.8M) | (686.7M) | |
Accounts Payable | 5.9M | 3.6M | 3.7M | 6.4M | 11.5M | 12.1M | |
Cash | 41.4M | 174.0M | 92.3M | 167.5M | 139.5M | 93.7M | |
Non Current Assets Total | 35.5M | 34.7M | 46.4M | 33.1M | 23.2M | 21.7M | |
Non Currrent Assets Other | 490K | 2.0M | 6.0M | 5.3M | 3.7M | 2.6M | |
Other Assets | 3.6M | 20.5M | 6.0M | 8.4M | 9.7M | 5.4M | |
Cash And Short Term Investments | 91.4M | 174.0M | 130.4M | 202.3M | 139.5M | 119.8M | |
Common Stock Total Equity | 26K | 34K | 43K | 56K | 20K | 28.2K | |
Common Stock Shares Outstanding | 4.0M | 4.6M | 6.3M | 12.6M | 28.3M | 29.7M | |
Short Term Investments | 39.8M | 49.8M | 50.0M | 0.0 | 38.1M | 34.8M | |
Liabilities And Stockholders Equity | 150.0M | 213.3M | 182.9M | 244.5M | 168.2M | 147.5M | |
Non Current Liabilities Total | 47.3M | 94.1M | 66.2M | 86.0M | 114.8M | 120.6M | |
Other Current Assets | 2.6M | 2.2M | 3.2M | 7.4M | 5.5M | 2.8M | |
Other Stockholder Equity | 372.1M | 467.5M | 548.8M | 685.8M | 739.4M | 377.3M | |
Total Liab | 70.8M | 122.7M | 97.7M | 116.8M | 151.5M | 159.1M | |
Property Plant And Equipment Gross | 31.9M | 29.6M | 37.1M | 37.2M | 27.1M | 19.9M | |
Total Current Assets | 114.5M | 178.6M | 136.6M | 211.4M | 145.0M | 125.8M | |
Accumulated Other Comprehensive Income | 24K | 0.0 | (79K) | 102K | 117.3K | 123.2K | |
Short Term Debt | 1.3M | 3.5M | 4.0M | 4.1M | 11.3M | 11.9M | |
Common Stock | 34K | 43K | 56K | 61K | 20K | 32.1K | |
Property Plant Equipment | 31.9M | 14.2M | 27.3M | 11.4M | 13.1M | 12.6M | |
Short Long Term Debt Total | 25.9M | 66.2M | 65.2M | 63.6M | 62.1M | 34.7M | |
Long Term Debt Total | 22K | 621K | 39.6M | 40.6M | 46.7M | 49.1M | |
Capital Surpluse | 296.1M | 372.1M | 467.5M | 685.8M | 788.7M | 828.2M | |
Current Deferred Revenue | 5.7M | 12.2M | 10.2M | 4.3M | 5.0M | 6.4M | |
Retained Earnings Total Equity | (217.5M) | (293.0M) | (377.0M) | (558.2M) | (502.4M) | (477.3M) | |
Capital Lease Obligations | 25.9M | 26.7M | 24.9M | 22.9M | 20.9M | 16.7M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.